Why Is Osteoporosis Drugs Market Growing with Rising Awareness?

A number of factors, such as the surging prevalence of osteoporosis in females, growing awareness about the disease and its treatment, rising investments by market players for the development of drugs, and increasing expenditure on healthcare, are projected to boost the growth of the osteoporosis drugs market at a CAGR of 3.8% in the forecast period (2016–2022). At this growth rate, the market size is expected to reach $11,482.1 million by 2022 from $8,835.4 million in 2015.

Receive Sample Pages of this Report: https://www.psmarketresearch.com/market-analysis/osteoporosis-drugs-market/report-sample

The primary factor improving the osteoporosis drugs market growth prospects is the increasing prevalence of osteoporosis. According to the World Health Organization (WHO) data, around 55% of the population currently lives in urban areas, globally, with the share expected to reach about 68% by 2050. Urbanization leads to an unhealthy lifestyle, which negatively impacts bone health. This results in a large number of individuals suffering from the disease; therefore, the demand for osteoporosis drugs will increase during the forecast period for the treatment of this condition.

Make an Enquiry before Purchase: https://www.psmarketresearch.com/send-enquiry?enquiry-url=osteoporosis-drugs-market

The drug class segment of the osteoporosis drugs market is categorized into parathyroid hormone therapy, bisphosphonates, selective estrogen receptor modulator (SERM), calcitonin, rank ligand inhibitor, and others. Among these, the bisphosphonates category accounted for the largest share in 2015 in the market. On the other hand, the rank ligand inhibitor category is projected to observe the highest CAGR in the coming years.

The osteoporosis drugs market is quite competitive in nature, owing to the presence of several key players who have a large product portfolio. The players are developing highly efficient drugs for the management of osteoporosis. These companies are additionally adopting strategies such as mergers and acquisitions to improve their market position. The key market players include F. Hoffmann-La Roche, Eli Lilly and Company, GlaxoSmithKline plc, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Novartis International AG, Radius Health Inc., Merck & Co. Inc., and Amgen Inc.

Thus, the increasing prevalence of osteoporosis and the surging healthcare expenditure across the globe are expected to propel the growth of the market during the forecast period.

About P&S Intelligence
P&S Intelligence is a provider of market research and consulting services catering to the market information needs of burgeoning industries across the world. Providing the plinth of market intelligence, P&S as an enterprising research and consulting company, believes in providing thorough landscape analyses on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness.

Contact:
P&S Intelligence
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@psmarketresearch.com

This release was published on openPR.